Table 2.
Characteristics of included studies for treatment response to EGFR-TKIs.
| Author | Year | ORR# | Non-ORR# | DCR& | Non-DCR& | Response criteria |
|---|---|---|---|---|---|---|
| Zheng L | 2013 | 3/33 | 18/69 | 12/77 | 9/25 | RECIST v1.1 |
| Isobe K | 2014 | 8/37 | 5/20 | 13/52 | 0/5 | NR |
| Zhao MC | 2014 | 4/99 | 12/51 | 10/122 | 6/28 | RECIST v1.1 |
| Lee JY cohort 1 | 2015 | 29/146 | 3/27 | 30/163 | 2/10 | RECIST v1.1 |
| Lee JY cohort 2 | 2015 | 7/45 | 3/14 | 10/55 | 0/4 | RECIST v1.1 |
| Cardona AF | 2016 | 5/55 | 9/20 | NR | NR | NR |
| Sun S | 2017 | 16/63 | 17/37 | 31/97 | 2/3 | RECIST v1.1 |
| Qian K | 2017 | 4/27 | 10/41 | 12/63 | 2/5 | RECIST |
| Wang F | 2019 | 4/64 | 14/83 | 14/137 | 4/10 | RECIST v1.0 |
| Incharoen P | 2019 | 13/41 | 7/36 | 18/65 | 2/12 | RECIST v1.1 |
| Liu SY CTONG0901 | 2020 | 12/97 | 10/75 | 20/152 | 2/20 | NR |
| Liu SY GLCI | 2020 | 13/71 | 11/46 | 22/113 | 2/4 | NR |
| Ariyasu R | 2020 | 22/117 | 5/23 | NR | NR | RECIST v1.1 |
| Li XZ | 2021 | 7/62 | 18/56 | 22/106 | 3/12 | RECIST v1.1 |
#Number of patients who achieved objective response (ORR) and who did not achieve objective response (non-ORR) in the BIM deletion group/wild-type group, respectively. &Number of patients who achieved disease control (DCR) and who did not achieve disease control (non-DCR) in the BIM deletion group/wild-type group, respectively. ORR: objective response rate; DCR: disease control rate; RECIST: Response Evaluation Criteria in Solid Tumors; NR: not reported.